brennan, Author at Patients For Affordable Drugs

Patients For Affordable Drugs Now slammed the inclusion of the ORPHAN Cures Act in the package. This provision widens the types of drugs excluded from the drug price negotiation program under 2022’s Inflation Reduction Act.

“By letting high-cost drugs with multiple orphan uses avoid negotiation and extending the timeline before negotiation for other medications, lawmakers have handed pharmaceutical corporations a new and unnecessary way to protect monopoly pricing—all while one in three Americans can’t afford their medications,” said Merith Basey, executive director of the organization.

FierceHealthcare: House GOP advances budget megabill, imposing stricter Medicaid work requirements